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Clinical PerspectiveWhat Is New?Data comparing prognostic outcomes of patients presenting with ventricular tachyarrhythmias and sudden cardiac arrest depending on the presence or absence of acute myocardial infarction (AMI) is rare.High‐risk patients with ventricular tachyarrhythmias and sudden cardiac arrest without AMI were associated with higher mortality compared with AMI, whereas non--ST‐segment--elevation myocardial infarction (NSTEMI) was associated with higher all‐cause mortality compared with ST‐segment--elevation myocardial infarction (STEMI).Ventricular tachyarrhythmias ≥48 hours after AMI were associated with higher long‐term all‐cause mortality.The strongest predictors of death across all subgroups---non‐AMI, AMI, NSTEMI, STEMI---were cardiogenic shock, cardiopulmonary resuscitation, progressive heart failure, and concomitant chronic kidney disease.What Are the Clinical Implications?Ventricular tachyarrhythmias in STEMI patients may more likely be attributable to the infarct itself without pre‐existing heart failure, whereas ventricular tachyarrhythmias in non‐AMI and NSTEMI patients may more often be associated with heart failure progression.Patients presenting with ventricular tachyarrhythmias and sudden cardiac arrest may profit from coronary angiography to exclude or treat relevant coronary artery disease, irrespective of the presence or absence of AMI.

Introduction {#jah33501-sec-0008}
============

Ventricular tachyarrhythmias and sudden cardiac arrest (SCA) are usually caused by an acute coronary syndrome and associated with an adverse clinical outcome.[1](#jah33501-bib-0001){ref-type="ref"}, [2](#jah33501-bib-0002){ref-type="ref"}, [3](#jah33501-bib-0003){ref-type="ref"}, [4](#jah33501-bib-0004){ref-type="ref"} Patients with ST‐segment--elevation myocardial infarction (STEMI) should undergo coronary angiography within 60 to 120 minutes, whereas patients with non--ST‐segment--elevation myocardial infarction (NSTEMI) no later than 72 hours, respectively.[5](#jah33501-bib-0005){ref-type="ref"} The risk of an irreversible myocardial ischemia, alleviating the development of focal or non‐focal arrhythmogenic sources degenerating into ventricular tachycardia (VT) or fibrillation (VF) was shown to be the highest within 72 hours.[6](#jah33501-bib-0006){ref-type="ref"}, [7](#jah33501-bib-0007){ref-type="ref"} Additionally, ventricular tachyarrhythmias and SCA can be caused by other etiologies beyond myocardial infarction, including cardiomyopathies, channelopathies, myocarditis, electrolyte disorders or trauma.[8](#jah33501-bib-0008){ref-type="ref"} These conditions may partly be associated with an increase of cardiac troponins reflecting the presence of type 2 myocardial infarction without evidence of a critical coronary artery stenosis.[9](#jah33501-bib-0009){ref-type="ref"}, [10](#jah33501-bib-0010){ref-type="ref"}

Patients suffering from acute myocardial infarction (AMI) are characterized as high‐risk in the presence of life‐threatening ventricular tachyarrhythmias, aborted cardiac arrest, hemodynamic instability, or cardiogenic shock. However, these high‐risk patients are not well represented in randomized controlled trials and reliable data about their long‐term prognosis are limited.[9](#jah33501-bib-0009){ref-type="ref"} Accordingly, recommendations of international guidelines are heterogeneous for AMI patients complicated by ventricular tachyarrhythmias.

Therefore, this study evaluates the differences of prognostic outcomes depending on the presence of AMI, NSTEMI and STEMI in consecutive patients presenting with ventricular tachyarrhythmias and SCA on admission.

Methods {#jah33501-sec-0009}
=======

Study Patients, Design, and Data Collection {#jah33501-sec-0010}
-------------------------------------------

The present study retrospectively included all consecutive patients presenting with ventricular tachyarrhythmias or SCA on hospital admission from 2002 until 2016 at the First Department of Medicine, University Medical Centre Mannheim, Germany. Using the hospital information system, all relevant clinical data related to the index event was documented. The data, analytic methods, and study materials will be made available to other researchers for purposes of reproducing the results or replicating the procedure on reasonable personal request to the corresponding author.

Ventricular tachyarrhythmias comprised VT and VF, as defined by current international guidelines.[8](#jah33501-bib-0008){ref-type="ref"}, [9](#jah33501-bib-0009){ref-type="ref"} Sustained VT was defined by duration of \>30 seconds or causing hemodynamic collapse within 30 seconds, and non‐sustained VT by duration of \<30 seconds both characterized by wide QRS complexes (≥120 ms) at a rate greater than 100 beats per minute. Ventricular tachyarrhythmias were documented by 12‐lead electrocardiogram (ECG), ECG tele‐ monitoring, implantable cardioverter defibrillator (ICD) or in case of unstable course or during cardiopulmonary resuscitation (CPR) by external defibrillator monitoring. Documented VF was treated by external defibrillation and in case of prolonged instability with additional intravenous anti‐arrhythmic drugs during CPR. Onset of VT was stratified into VT occurring \<48 hours and ≥48 hours of AMI onset. High‐risk criteria in the setting of AMI comprised the presence of life‐threatening ventricular tachyarrhythmias, aborted cardiac arrest, hemodynamic instability, or cardiogenic shock.[10](#jah33501-bib-0010){ref-type="ref"}

Further data being documented contained baseline characteristics, prior medical history, prior medical treatment, length of index stay, detailed findings of laboratory values at baseline, data derived from all non‐invasive or invasive cardiac diagnostics and device therapies, such as coronary angiography, electrophysiological examination, ICD, pacemaker or cardiac contractility modulation, as well as imaging modalities, such as echocardiography or cardiac magnetic resonance imaging. The overall presence of ICDs comprised the total sum of all patients with either a prior implanted ICD before admission, those undergoing new ICD implantation at index stay, as well as those with ICD implantation at the complete follow‐up period after index hospitalization, referring to conventional ICD, subcutaneous‐ICD (s‐ICD) and cardiac resynchronization therapy with defibrillator function (CRT‐D). Pharmacological treatment was documented according to the discharge medication of patients surviving index hospitalization. Rates of overall ICDs and of pharmacological therapies are referred to the number of surviving patients being discharged from index hospitalization.

Every re‐visit at the outpatient clinic or rehospitalization was documented when related to recurrent ventricular tachyarrhythmias and adverse cardiac events. Adverse cardiac events comprised acute heart failure, CPR, cardiac surgery, recurrent percutaneous coronary intervention (re‐PCI), new implants or upgrades of cardiac devices, worsening or improvement of left ventricular function.

Documentation period lasted from index event until 2016. Documentation of all medical data was performed by independent cardiologists at the time of the patients′ clinical presentation at our institution, being masked to final data analyses.

The present study is derived from an analysis of the "*R*egistry of Malignant *A*rrhythmias and Sudden *C*ardiac D*e*ath---*I*nfluence of Diagnostics and In*t*erventions (RACE‐IT)" and represents a single‐center registry including consecutive patients presenting with ventricular tachyarrhythmias and SCA being acutely admitted to the University Medical Center Mannheim (UMM), Germany (ClinicalTrials.gov identifier: NCT02982473) from 2002 until 2016. The registry was performed according to the principles of the declaration of Helsinki and was approved by the medical ethics committee II of the Faculty of Medicine Mannheim, University of Heidelberg, Germany, which waived the requirement for informed consent.

The medical center covers a general emergency department for emergency admission of traumatic, surgical, neurological, and cardiovascular conditions. Interdisciplinary consultation is an in‐built feature of this 24/7 service, and connects to a stroke unit, 4 intensive care units with extracorporeal life support and a chest pain unit to alleviate rapid triage of patients. The cardiologic department itself includes cardiac catheterization and electrophysiologic laboratories, a hybrid operating room, and telemetry units.

Definition of Study Groups, Inclusion and Exclusion Criteria {#jah33501-sec-0011}
------------------------------------------------------------

For the present analysis risk‐stratification was performed according to the presence of AMI versus non‐AMI, and STEMI versus NSTEMI according to European guidelines.[5](#jah33501-bib-0005){ref-type="ref"}, [8](#jah33501-bib-0008){ref-type="ref"}, [10](#jah33501-bib-0010){ref-type="ref"}, [12](#jah33501-bib-0012){ref-type="ref"} STEMI was defined as a novel rise in the ST segment in at least two contiguous leads with ST‐segment elevation ≥2.5 mm in men \<40 years, ≥2 mm in men ≥40 years, or ≥1.5 mm in women in leads V2--V3 and/or 1 mm in the other leads. Additional ECG criteria were new ST depression or inversion, T wave alterations, Q waves or new left bundle branch block. NSTEMI was defined as the presence of an acute coronary syndrome with a troponin I increase of above the 99th percentile of a healthy reference population in the absence of ST segment elevation, but persistent or transient ST segment depression, inversion or alteration of T wave, or normal ECG, in the presence of a coronary culprit lesion. The culprit lesion was defined as an acute complete thrombotic occlusion for STEMI and any relevant critical coronary stenosis for NSTEMI with the potential need for coronary revascularization either by PCI or coronary artery bypass grafting. The presence of coronary culprit lesion was mandatory for both diagnoses of NSTEMI and STEMI. Evidence of regional wall motion abnormalities was also included in AMI diagnosis as far as available. Values of left ventricular ejection fraction (LVEF) were retrieved from standardized transthoracic echocardiographic examinations usually being performed before hospital discharge in survivors to assess realistic LVEF values beyond the acute phase of acute coronary ischemia during AMI. In minor part and only if available, earlier LVEF values assessed on admission or during intensive care were retrieved from patients who died already within the acute phase of AMI.

Overall exclusion criteria comprised patients without complete follow‐up data regarding mortality. Each patient was counted only once for inclusion when presenting with the first episode of ventricular tachyarrhythmias or SCA.

Study End Points {#jah33501-sec-0012}
----------------

The primary prognostic end point was all‐cause mortality at long‐term follow‐up. Secondary end points were all‐cause mortality at 30 days, at index hospitalization, early cardiac death at 24 hours and first re‐PCI at long‐term follow‐up. Early cardiac death was defined as occurring \<24 hours after onset of ventricular tachyarrhythmias or an assumed unstable cardiac condition on index admission.

Overall follow‐up period lasted until 2016. All‐cause mortality was documented using our electronic hospital information system and by directly contacting state resident registration offices ("bureau of mortality statistics") across Germany. Identification of patients was verified by place of name, surname, day of birth and registered living address. Lost to follow‐up rate was 1.7% (n=48) regarding survival until the end of the follow‐up period.

Statistical Methods {#jah33501-sec-0013}
-------------------

Quantitative data are presented as mean±standard error of mean (SEM), median and interquartile range (IQR), and ranges depending on the distribution of the data and were compared using the Student *t* test for normally distributed data or the Mann--Whitney *U* test for nonparametric data. Deviations from a Gaussian distribution were tested by the Kolmogorov--Smirnov test. Spearman\'s rank correlation for nonparametric data was used to test univariate correlations. Qualitative data are presented as absolute and relative frequencies and compared using the Chi^2^ test or the Fisher\'s exact test, as appropriate.

Firstly, overall data of consecutive patients on admission are given for the entire unmatched cohort to present the real‐life character of healthcare supply at our institution in between 2002 and 2016. Here, multivariable Cox regression models were applied for the evaluation of the primary prognostic end point within the total study cohort for non‐AMI versus AMI, and in the AMI subgroup for NSTEMI versus STEMI. Then, multivariable Cox regression models were applied for the primary prognostic end point in the subgroups of non‐AMI, STEMI, and NSTEMI patients. Multivariable Cox regression models were adjusted for the following covariables: age, sex, diabetes mellitus, chronic kidney disease (glomerular filtration rate \<60 mL/min per 1.73 m^2^), prior heart failure, prior AMI, prior coronary artery disease (CAD), LVEF \<35%, CPR, index AMI, overall presence of ICD, and index ventricular tachyarrhythmia (ie, VT/VF).

Secondly, propensity score matching was applied. There is a relevant and increasing demand from patients, clinicians and within the healthcare system in general for growing evidence from non‐randomized studies. There are simply too many medically relevant hypotheses, which will never be investigated within randomized controlled trials because of several reasons (ie, funding, recruitment, difficult study settings, high‐risk patients, etc). Therefore, we felt that the method of propensity matching would be a reasonable additional statistical method beside multivariable Cox regression models for the purpose of the present study evaluating the prognostic impact of non‐AMI/AMI and NSTEMI/STEMI in high‐risk patients presenting with ventricular tachyarrhythmias and SCA on admission. These high‐risk patients are usually excluded from randomized controlled trials. In randomized controlled trials patients with or without a specific treatment would have a 50% chance to be treated and balanced measured and unmeasured baseline characteristics would be expected. However, patients with different disease entities may not be randomized in real‐life (such as non‐AMI versus AMI, or STEMI versus NSTEMI) because of different pathophysiologies and treatment recommendations. An observational study usually recruits consecutive real‐life patients without randomization resulting in varying chances between 0% and 100% to receive imbalances in baseline characteristics and treatments. Therefore, differences of outcomes in specific disease groups might be explained by heterogeneous distribution of baseline characteristics and applied therapies. To further reduce this selection bias, we used 1:1 propensity‐scores for AMI versus non‐AMI, respectively STEMI versus NSTEMI patients, to assemble matched and well‐balanced subgroups. One‐to‐one ratio for propensity score matching was performed including the entire study cohort and in AMI patients, applying a non‐parsimonious multivariable logistic regression model using AMI and STEMI patients as the dependent variables, respectively.[13](#jah33501-bib-0013){ref-type="ref"}, [14](#jah33501-bib-0014){ref-type="ref"}

Propensity scores were created according to the presence of the following independent variables: age, sex, diabetes mellitus, chronic kidney disease (glomerular filtration rate \<60 mL/min per 1.73 m^2^), prior heart failure, prior AMI, prior CAD, LVEF, CPR, cardiogenic shock, index AMI, overall presence of ICD, and index ventricular tachyarrhythmia (ie, VT/VF). Based on the propensity score values counted by logistic regression, for each patient in the AMI group (STEMI group, respectively) one patient in the control group with a similar propensity score value was found (accepted difference of propensity score values \<5%). Propensity scores were calculated for the following comparative analyses: (1) non‐AMI versus AMI (2) NSTEMI versus STEMI. Uni‐variable stratification was performed using the Kaplan--Meier method with comparisons between groups using univariable hazard ratios (HR) given together with 95% confidence intervals, according to the presence of AMI, STEMI, and NSTEMI within the propensity‐matched cohorts.

Follow‐up periods at 30 days defined short‐term and at 2.5 years defined long‐term follow‐up. Long‐term follow‐up period of 2.5 years accorded to the median survival time of AMI patients to guarantee complete follow‐up of at least 50% of patients. Patients not meeting long‐term follow‐up were censored.

The result of a statistical test was considered significant for *P*\<0.05, *P*≤0.1 was defined as a statistical trend. SAS, release 9.4 (SAS Institute Inc, Cary, NC, USA) and SPSS (Version 25, IBM Armonk, New York, USA) were used for statistics.

Results {#jah33501-sec-0014}
=======

Entire, Unmatched Real‐Life Cohort {#jah33501-sec-0015}
----------------------------------

In the entire, unmatched real‐life cohort including a total of 2813 high‐risk patients, the prevalence of AMI was 29%, of which 10% presented with STEMI and 19% with NSTEMI. Most patients were males. As shown in Table [1](#jah33501-tbl-0001){ref-type="table"} (left columns), non‐AMI patients had higher rates of VT, were older, as well had higher rates of prior heart failure, prior ICD, dilative cardiomyopathy, atrial fibrillation, LVEF \<35% and overall ICDs (*P*\<0.05). In contrast, AMI patients revealed higher rates of VF, early cardiac death, CPR, cardiogenic shock, CAD including multivessel CAD and prior coronary artery bypass grafting, PCI, chronic kidney disease, heart failure, statin and antiplatelet medication, whereas LVEF \>55% was more common in AMI patients (*P*\<0.05) (Table [1](#jah33501-tbl-0001){ref-type="table"}, left columns).Notably, patients with AMI‐related VT ≥48 hours after AMI onset (early cardiac deaths excluded) were associated with higher mortality compared with AMI‐related VT \<48 hours already at 30 days (un‐matched cohort: 30 days, HR=2.289; 95% confidence interval \[CI\] 1.028--5.047, *P*=0.040; 2.5 years, HR=2.661, 95% CI 1.469--4.820; *P*=0.001), irrespective of the presence of STEMI or NSTEMI (Table [S1](#jah33501-sup-0001){ref-type="supplementary-material"}).

###### 

Baseline Characteristics in the Unmatched Real‐Life Population

  Characteristic                        AMI (n=825; 29%)   Non‐AMI (n=1986; 71%)   *P* Value                                      STEMI (n=276; 10%)   NSTEMI (n=549; 19%)   *P* Value
  ------------------------------------- ------------------ ----------------------- ---------------------------------------------- -------------------- --------------------- ----------------------------------------------
  Inclusion criteria, n (%)                                                                                                                                                  
  Ventricular tachycardia               248 (30)           1116 (56)               0.001[a](#jah33501-note-0003){ref-type="fn"}   81 (29)              167 (30)              0.752
  Ventricular fibrillation              443 (54)           615 (31)                0.001[a](#jah33501-note-0003){ref-type="fn"}   156 (57)             287 (52)              0.249
  Early cardiac death                   286 (35)           517 (26)                0.001[a](#jah33501-note-0003){ref-type="fn"}   84 (30)              202 (37)              0.070
  With VT                               49 (6)             85 (4)                  0.060                                          11 (4)               38 (7)                0.092
  With VF                               108 (13)           187 (9)                 0.004[a](#jah33501-note-0003){ref-type="fn"}   35 (13)              73 (13)               0.805
  Without ventricular tachyarrhythmia   134 (16)           257 (13)                0.021[a](#jah33501-note-0003){ref-type="fn"}   39 (14)              95 (17)               0.244
  Sex, n (%)                                                                                                                                                                 
  Male                                  612 (74)           1368 (69)               0.005[a](#jah33501-note-0003){ref-type="fn"}   206 (75)             406 (74)              0.832
  Age, median (range)                   68 (19--100)       68 (14--97)             0.035[a](#jah33501-note-0003){ref-type="fn"}   65 (25--91)          69 (19--100)          0.001[a](#jah33501-note-0003){ref-type="fn"}
  Cardiovascular risk factors, n (%)                                                                                                                                         
  Arterial hypertension                 482 (58)           1078 (54)               0.044[a](#jah33501-note-0003){ref-type="fn"}   148 (54)             334 (61)              0.047[a](#jah33501-note-0003){ref-type="fn"}
  Diabetes mellitus                     238 (29)           513 (26)                0.100                                          66 (24)              172 (31)              0.027[a](#jah33501-note-0003){ref-type="fn"}
  Hyperlipidemia                        205 (25)           515 (26)                0.549                                          53 (19)              152 (28)              0.008[a](#jah33501-note-0003){ref-type="fn"}
  Smoking                               283 (34)           422 (21)                0.001[a](#jah33501-note-0003){ref-type="fn"}   112 (41)             171 (31)              0.007[a](#jah33501-note-0003){ref-type="fn"}
  Cardiac family history                75 (9)             157 (8)                 0.298                                          26 (9)               49 (9)                0.815
  Comorbidities, n (%)                                                                                                                                                       
  Prior heart failure                   113 (14)           517 (26)                0.001[a](#jah33501-note-0003){ref-type="fn"}   22 (8)               91 (17)               0.001[a](#jah33501-note-0003){ref-type="fn"}
  Prior CAD                             297 (36)           792 (40)                0.054                                          79 (29)              218 (40)              0.002[a](#jah33501-note-0003){ref-type="fn"}
  Prior myocardial infarction           164 (20)           449 (23)                0.111                                          41 (15)              123 (22)              0.010[a](#jah33501-note-0003){ref-type="fn"}
  Preexisting ICD                       12 (1)             256 (13)                0.001[a](#jah33501-note-0003){ref-type="fn"}   1 (0.4)              11 (2)                0.063
  Dilative cardiomyopathy               0 (0)              259 (13)                ···                                            0 (0)                0 (0)                 ···
  Cardiogenic shock                     283 (34)           284 (14)                0.001[a](#jah33501-note-0003){ref-type="fn"}   91 (33)              192 (35)              0.568
  Atrial fibrillation                   197 (24)           613 (31)                0.001[a](#jah33501-note-0003){ref-type="fn"}   52 (19)              145 (26)              0.016[a](#jah33501-note-0003){ref-type="fn"}
  Chronic kidney disease                459 (56)           987 (49)                0.004[a](#jah33501-note-0003){ref-type="fn"}   141 (51)             318 (58)              0.062
  Hyperkalemia                          28 (3)             62 (3)                  0.709                                          4 (1)                24 (4)                0.029[a](#jah33501-note-0003){ref-type="fn"}
  Hypokalemia                           36 (4)             111 (6)                 0.184                                          10 (4)               26 (5)                0.460
  COPD/asthma                           69 (8)             221 (12)                0.028[a](#jah33501-note-0003){ref-type="fn"}   13 (5)               56 (10)               0.007[a](#jah33501-note-0003){ref-type="fn"}
  Stroke                                28 (3)             55 (3)                  0.373                                          9 (3)                19 (3)                0.881
  Left ventricular function, n (%)                                                                                                                                           
  LVEF ≥55%                             169 (20)           414 (21)                0.830                                          61 (22)              108 (20)              0.415
  LVEF 54% to 35%                       219 (27)           430 (22)                0.005[a](#jah33501-note-0003){ref-type="fn"}   80 (28)              139 (25)              0.260
  LVEF \<35%                            165 (20)           546 (27)                0.001[a](#jah33501-note-0003){ref-type="fn"}   48 (17)              117 (21)              0.184
  Not documented                        272 (···)          596 (···)               0.122                                          87 (···)             185 (···)             0.530
  Cardiac therapy at index, n (%)                                                                                                                                            
  Cardiopulmonary resuscitation         628 (76)           878 (44)                0.001[a](#jah33501-note-0003){ref-type="fn"}   211 (76)             417 (76)              0.875
  In hospital                           270 (33)           403 (20)                0.001[a](#jah33501-note-0003){ref-type="fn"}   90 (33)              180 (33)              0.959
  Out of hospital                       358 (43)           475 (24)                0.001[a](#jah33501-note-0003){ref-type="fn"}   121 (44)             237 (43)              0.854
  Coronary artery disease, n (%)                                                                                                                                             
  Coronary angiography, overall         662 (80)           882 (44)                0.001[a](#jah33501-note-0003){ref-type="fn"}   241 (87)             421 (77)              0.001[a](#jah33501-note-0003){ref-type="fn"}
  Coronary artery disease               652 (79)           508 (26)                0.001[a](#jah33501-note-0003){ref-type="fn"}   238 (86)             414 (75)              0.001[a](#jah33501-note-0003){ref-type="fn"}
  No evidence of CAD                    10 (1)             374 (19)                0.001[a](#jah33501-note-0003){ref-type="fn"}   3 (1)                7 (1.2)               0.816
  1‐vessel                              208 (25)           144 (7)                 0.001[a](#jah33501-note-0003){ref-type="fn"}   84 (30)              124 (23)              0.014[a](#jah33501-note-0003){ref-type="fn"}
  2‐vessel                              208 (25)           148 (7)                 0.001[a](#jah33501-note-0003){ref-type="fn"}   77 (28)              131 (24)              0.208
  3‐vessel                              236 (29)           216 (11)                0.001[a](#jah33501-note-0003){ref-type="fn"}   77 (28)              159 (29)              0.750
  CTO                                   171 (19)           154 (23)                0.065                                          34 (14)              120(29)               0.001[a](#jah33501-note-0003){ref-type="fn"}
  Prior CABG                            40 (5)             156 (8)                 0.004[a](#jah33501-note-0003){ref-type="fn"}   8 (3)                32 (6)                0.064
  Intracoronary thrombus                121 (15)           15 (0.8)                0.001[a](#jah33501-note-0003){ref-type="fn"}   62 (22)              59 (11)               0.001[a](#jah33501-note-0003){ref-type="fn"}
  CPR during coronary angiography       104 (13)           38 (2)                  0.001[a](#jah33501-note-0003){ref-type="fn"}   34 (12)              70 (13)               0.860
  PCI, n (%)                            549 (67)           171 (9)                 0.001[a](#jah33501-note-0003){ref-type="fn"}   223 (81)             326 (59)              0.001[a](#jah33501-note-0003){ref-type="fn"}
  Target lesions, n (%)                                                                                                                                                      
  RCA                                   190 (23)           74 (4)                  0.001[a](#jah33501-note-0003){ref-type="fn"}   81 (29)              109 (20)              0.002[a](#jah33501-note-0003){ref-type="fn"}
  LMT                                   37 (4)             16 (0.8)                0.001[a](#jah33501-note-0003){ref-type="fn"}   9 (3)                28 (5)                0.228
  LAD                                   289 (35)           72 (4)                  0.001[a](#jah33501-note-0003){ref-type="fn"}   128 (46)             161 (29)              0.001[a](#jah33501-note-0003){ref-type="fn"}
  LCX                                   136 (16)           40 (2)                  0.001[a](#jah33501-note-0003){ref-type="fn"}   47 (17)              89 (16)               0.732
  RIM                                   8 (1)              7 (0.4)                 0.041[a](#jah33501-note-0003){ref-type="fn"}   1 (0.4)              7 (1)                 0.207
  Bypass graft                          8 (1)              9 (0.5)                 0.108                                          2 (0.7)              6 (1)                 0.611
  Sent to CABG                          27 (3)             19 (1)                  0.001[a](#jah33501-note-0003){ref-type="fn"}   4 (1)                23 (4)                0.037[a](#jah33501-note-0003){ref-type="fn"}
  Patients discharged                   409 (50)           1288 (65)               0.001[a](#jah33501-note-0003){ref-type="fn"}   153 (55)             265 (48)              0.052
  Overall ICDs, n (%)                   726 (56)           112 (27)                0.001[a](#jah33501-note-0003){ref-type="fn"}   23 (15)              89 (34)               0.001[a](#jah33501-note-0003){ref-type="fn"}
  Medication at discharge, n (%)                                                                                                                                             
  Beta‐blocker                          377 (92)           977 (76)                0.001[a](#jah33501-note-0003){ref-type="fn"}   143 (93)             234 (88)              0.088
  ACE inhibitor                         326 (80)           724 (56)                0.001[a](#jah33501-note-0003){ref-type="fn"}   123 (80)             203 (77)              0.368
  ARB                                   22 (5)             164 (13)                0.001[a](#jah33501-note-0003){ref-type="fn"}   8 (5)                14 (5)                0.981
  Aldosterone antagonist                31 (8)             150 (12)                0.020[a](#jah33501-note-0003){ref-type="fn"}   13 (8)               18 (7)                0.522
  Digitalis                             27 (7)             182 (14)                0.001[a](#jah33501-note-0003){ref-type="fn"}   4 (3)                23 (9)                0.015[a](#jah33501-note-0003){ref-type="fn"}
  Amiodarone                            51 (12)            208 (16)                0.071                                          8 (5)                43 (16)               0.001[a](#jah33501-note-0003){ref-type="fn"}
  ASA only                              55 (13)            392 (30)                0.001[a](#jah33501-note-0003){ref-type="fn"}   9 (6)                46 (17)               0.001[a](#jah33501-note-0003){ref-type="fn"}
  Clopidogrel only                      8 (2)              38 (3)                  0.352                                          2 (1)                6 (2)                 0.492
  Dual antiplatelet therapy             338 (83)           136 (11)                0.001[a](#jah33501-note-0003){ref-type="fn"}   141 (92)             197 (74)              0.001[a](#jah33501-note-0003){ref-type="fn"}
  Statin                                379 (93)           643 (50)                0.001[a](#jah33501-note-0003){ref-type="fn"}   145 (95)             234 (88)              0.028[a](#jah33501-note-0003){ref-type="fn"}

ACE indicates angiotensin‐converting enzyme; AMI, acute myocardial infarction; ARB, angiotensin receptor blocker; ASA, acetyl salicylic acid; CABG, coronary artery bypass grafting; CAD, coronary artery disease; CTO, chronic total occlusion; ICD; internal cardioverter defibrillator; LAD, left artery descending; LVEF, left ventricular ejection fraction; LCX, left circumflex; LMT, left main trunk; PCI, percutaneous coronary intervention; RCA, right coronary artery; RIM, ramus intermedius; STEMI/NSTEMI, (non) ST segment myocardial infarction; VF, ventricular fibrillation; VT, ventricular tachycardia.

Indicates statistical significance at *P*\<0.05.

As shown in Table [1](#jah33501-tbl-0001){ref-type="table"} (right columns) comparing STEMI with NSTEMI patients, the rates of ventricular tachyarrhythmias and early cardiac deaths were equally distributed. Cardiovascular risk profile was higher in NSTEMI patients, alongside with higher rates of prior heart failure, prior CAD, prior AMI, atrial fibrillation, chronic kidney disease, LVEF \<55%, and overall ICDs (*P*\<0.05). In contrast, STEMI patients revealed higher rates of coronary 1‐vessel disease and PCI commonly at the right coronary artery and left artery descending with higher rates of intracoronary thrombus compared with NSTEMI patients (*P*\<0.05). Minor differences in statins and antiplatelet therapy due to modified regimens in selected patients during routine care (eg, in patients with increasing risk of bleeding or triple therapy) were present (Table [1](#jah33501-tbl-0001){ref-type="table"} \[right columns\]).

Index PCI was only of prognostic benefit in AMI, respectively in STEMI patients (AMI: univariable HR 0.732, *P*=0.021; STEMI: univariable HR 0.425, *P*=0.003), whereas this was not seen in NSTEMI and non‐AMI patients (*P*\>0.05) (data not shown).

Multivariable Cox regression analyses within the entire, unmatched real‐life cohort revealed non‐AMI patients to be significantly associated with the primary end point of long‐term all‐cause mortality at 2.5 years (HR=1.458, 95% CI 1.203--1.767, *P*=0.001) (Figure [1](#jah33501-fig-0001){ref-type="fig"}A, left panel). In the AMI subgroup, the presence of NSTEMI was significantly associated with long‐term all‐cause mortality at 2.5 years (HR=1.460, 95% CI 1.025--2.079, *P*=0.036) (Figure [1](#jah33501-fig-0001){ref-type="fig"}A, right panel).

![A, Non‐AMI (left) as well as NSTEMI (right) were still associated with the primary end point of long‐term all‐cause mortality at 2.5 years after adjusting for several prognosis‐relevant factors within multivariable Cox regression models. B, Multivariable Cox regression analyses evaluating the prognostic impact of clinical factors on the primary end point of long‐term all‐cause mortality at 2.5 years. Left : Model in non‐AMI patients; middle: Model in STEMI patients; right: model in NSTEMI patients. NSTEMI indicates non--ST‐segment--elevation myocardial infarction; AMI acute myocardial infarction; CAD, coronary artery disease; Card. Shock, cardiogenic shock; CI, confidence interval; CKD, chronic kidney disease; CPR, cardiopulmonary resuscitation; HF, heart failure; HR, hazard ratio; ICD, implanted cardioverter defibrillator; LVEF, left ventricular ejection fraction; STEMI, ST‐segment--elevation myocardial infarction; VF, ventricular fibrillation.](JAH3-7-e010004-g001){#jah33501-fig-0001}

Focusing on the subgroups of non‐AMI, NSTEMI, and STEMI patients (Figure [1](#jah33501-fig-0001){ref-type="fig"}B, left, middle, and right panels), multivariable Cox regressions revealed LVEF \<35%, cardiogenic shock, and chronic kidney disease as the strongest predictors of long‐term all‐cause mortality at 2.5 years in all subgroups. Particularly in non‐AMI patients, age \>72 years, prior CAD and CPR were significantly associated with the primary end point. In NSTEMI patients, age \>72 years and prior CAD, but not CPR were associated with the primary end point. Contrastively in STEMI patients, additional CPR, but neither age nor prior CAD were associated with long‐term all‐cause mortality.

Propensity‐Matched Cohorts {#jah33501-sec-0016}
--------------------------

After applying propensity‐score matching for the comparison of AMI versus non‐AMI patients (509 matched pairs) and STEMI versus NSTEMI patients (187 matched pairs) comparable subgroups with similar rates for age, sex, diabetes mellitus, chronic kidney disease, prior CAD, prior AMI, atrial fibrillation, LVEF, cardiogenic shock, CPR, and overall ICDs were achieved (Table [2](#jah33501-tbl-0002){ref-type="table"}, left and right columns).

###### 

Baseline Characteristics After Propensity Score Matching

  Characteristic                       Non‐AMI (n=509; 50%)   AMI (n=509; 50%)   *P* Value                                      STEMI (n=187; 50%)   NSTEMI (n=187; 50%)   *P* Value
  ------------------------------------ ---------------------- ------------------ ---------------------------------------------- -------------------- --------------------- ----------------------------------------------
  Inclusion criteria, n (%)                                                                                                                                                
  Ventricular tachycardia              212 (42)               182 (36)           0.024[a](#jah33501-note-0005){ref-type="fn"}   62 (33)              62 (33)               0.804
  Ventricular fibrillation             229 (45)               267 (53)           104 (56)                                       110 (59)                                   
  Early cardiac death                  68 (13)                60 (12)            0.450                                          21 (11)              15 (8)                0.293
  With VT                              27 (5)                 20 (4)             0.101                                          12 (6)               3 (2)                 0.005
  With VF                              52 (10)                35 (7)             19 (10)                                        7 (4)                                      
  Without VA                           68 (13)                60 (12)            15 (8)                                         21 (11)                                    
  Sex, n (%)                                                                                                                                                               
  Male                                 391 (77)               383 (75)           0.345                                          149 (80)             147 (79)              0.799
  Age, median (range)                  68 (16--92)            67 (19--100)       0.358                                          64 (25--91)          65 (19--100)          0.649
  Cardiovascular risk factors, n (%)                                                                                                                                       
  Arterial hypertension                307 (60)               321 (63)           0.367                                          107 (57)             112 (60)              0.600
  Diabetes                             147 (29)               146 (29)           0.945                                          45 (24)              49 (26)               0.633
  Hyperlipidemia                       140 (28)               145 (29)           0.727                                          43 (23)              50 (27)               0.402
  Smoking                              124 (24)               203 (40)           0.001[a](#jah33501-note-0005){ref-type="fn"}   89 (48)              80 (43)               0.350
  Cardiac family history               43 (8)                 54 (11)            0.240                                          21 (11)              19 (10)               0.738
  Comorbidities, n (%)                                                                                                                                                     
  Prior heart failure                  131 (26)               99 (19)            0.016[a](#jah33501-note-0005){ref-type="fn"}   19 (10)              28 (15)               0.160
  Prior CAD                            221 (43)               203 (40)           0.252                                          52 (28)              65 (35)               0.147
  Prior myocardial infarction          127 (25)               114 (22)           0.338                                          27 (14)              38 (20)               0.133
  Preexisting ICD                      48 (9)                 10 (2)             0.001[a](#jah33501-note-0005){ref-type="fn"}   1 (0.5)              2 (1)                 0.562
  Dilatative cardiomyopathy            40 (8)                 0 (0)              0.001[a](#jah33501-note-0005){ref-type="fn"}   0 (0)                0 (0)                 ···
  Cardiogenic shock                    123 (24)               141 (28)           0.198                                          47 (25)              44 (24)               0.718
  Atrial fibrillation                  157 (31)               148 (30)           0.538                                          45 (24)              44 (24)               0.903
  Chronic kidney disease               271 (53)               270 (53)           0.950                                          84 (45)              90 (48)               0.534
  Hyperkalemia                         40 (8)                 15 (3)             0.855                                          2 (1)                8 (4)                 0.054
  Hypokalemia                          29 (6)                 27 (5)             0.783                                          5 (3)                14 (8)                0.034[a](#jah33501-note-0005){ref-type="fn"}
  COPD/asthma                          54 (11)                46 (9)             0.400                                          9 (5)                23 (12)               0.012[a](#jah33501-note-0005){ref-type="fn"}
  Stroke                               15 (3)                 22 (4)             0.241                                          7 (4)                7 (4)                 1.000
  LVEF, n (%)                                                                                                                                                              
  LVEF ≥55%                            155 (31)               155 (31)           0.311                                          60 (32)              66 (35)               0.685
  LVEF 54% to 35%                      179 (35)               201 (39)           0.154                                          79 (42)              72 (39)               0.461
  LVEF \<35%                           175 (34)               153 (30)           0.140                                          48 (26)              49 (26)               0.905
  Cardiac therapies at index, n (%)                                                                                                                                        
  Cardiopulmonary resuscitation        327 (64)               346 (68)           0.208                                          133 (71)             136 (73)              0.730
  In hospital                          149 (29)               162 (32)           0.376                                          58 (31)              55 (30)               0.735
  Out of hospital                      178 (35)               184 (36)           0.694                                          75 (40)              81 (43)               0.529
  Coronary artery disease, n (%)                                                                                                                                           
  Coronary angiography overall         270 (53)               434 (85)           0.001[a](#jah33501-note-0005){ref-type="fn"}   171 (91)             160 (86)              0.075
  Coronary artery disease, n (%)       163 (60)               429 (99)           0.001[a](#jah33501-note-0005){ref-type="fn"}   187 (100)            183 (98)              0.988
  No evidence of CAD                   107 (40)               5 (1)              0.001[a](#jah33501-note-0005){ref-type="fn"}   0 (0)                4 (3)                 
  1‐vessel                             43 (16)                144 (33)           0.001[a](#jah33501-note-0005){ref-type="fn"}   66 (39)              61 (38)               0.635
  2‐vessel                             50 (19)                138 (32)           0.001[a](#jah33501-note-0005){ref-type="fn"}   59 (35)              44 (28)               0.119
  3‐vessel                             70 (26)                147 (34)           0.001[a](#jah33501-note-0005){ref-type="fn"}   46 (27)              51 (32)               0.594
  CTO                                  56 (21)                100 (23)           0.475                                          23 (14)              38 (24)               0.016[a](#jah33501-note-0005){ref-type="fn"}
  Prior CABG                           47 (17)                30 (7)             0.001[a](#jah33501-note-0005){ref-type="fn"}   7 (4)                12 (8)                0.183
  Intracoronary thrombus               6 (2)                  78 (18)            0.001[a](#jah33501-note-0005){ref-type="fn"}   50 (29)              20 (13)               0.001[a](#jah33501-note-0005){ref-type="fn"}
  CPR during coronary angiography      18 (7)                 39 (9)             0.273                                          12 (7)               13 (8)                0.703
  PCI, n (%)                           60 (22)                347 (80)           0.001[a](#jah33501-note-0005){ref-type="fn"}   171 (94)             121 (76)              0.001[a](#jah33501-note-0005){ref-type="fn"}
   Target lesions                                                                                                                                                          
  RCA                                  26 (5)                 123 (24)           0.001[a](#jah33501-note-0005){ref-type="fn"}   59 (32)              38 (20)               0.013[a](#jah33501-note-0005){ref-type="fn"}
  LMT                                  6 (1)                  13 (3)             0.105                                          2 (1)                4 (2)                 0.410
  LAD                                  29 (6)                 187 (37)           0.001[a](#jah33501-note-0005){ref-type="fn"}   95 (51)              60 (32)               0.001[a](#jah33501-note-0005){ref-type="fn"}
  RIM                                  4 (0.8)                5 (1)              0.738                                          0 (0)                3 (2)                 0.082
  RCX                                  14 (3)                 86 (17)            0.001[a](#jah33501-note-0005){ref-type="fn"}   33 (18)              30 (16)               0.679
  Bypass graft                         2 (0.4)                5 (1)              0.255                                          1 (0.5)              1 (0.5)               1.000
  Sent to CABG                         9 (2)                  23 (5)             0.012[a](#jah33501-note-0005){ref-type="fn"}   4 (2)                9 (5)                 0.158
  Patients discharged                  293 (58)               329 (65)           0.021[a](#jah33501-note-0005){ref-type="fn"}   134 (72)             117 (63)              0.061
  Overall ICDs, n (%)                  129 (44)               98 (30)            0.001[a](#jah33501-note-0005){ref-type="fn"}   21 (16)              29 (25)               0.071
  Medication at discharge, n (%)                                                                                                                                           
  Beta‐blocker                         225 (77)               302 (92)           0.001[a](#jah33501-note-0005){ref-type="fn"}   127 (95)             109 (93)              0.591
  ACE inhibitor                        172 (59)               261 (79)           0.001[a](#jah33501-note-0005){ref-type="fn"}   109 (81)             91 (78)               0.484
  ARB                                  31 (11)                18 (6)             0.017[a](#jah33501-note-0005){ref-type="fn"}   8 (6)                4 (3)                 0.388
  Aldosterone antagonist               16 (6)                 29 (9)             0.107                                          11 (8)               5 (4)                 0.203
  Digitalis                            44 (15)                20 (6)             0.001[a](#jah33501-note-0005){ref-type="fn"}   4 (3)                4 (3)                 1.000
  Amiodarone                           45 (15)                41 (13)            0.296                                          6 (5)                10 (9)                0.188
  ASA only                             93 (32)                48 (15)            0.001[a](#jah33501-note-0005){ref-type="fn"}   9 (7)                18 (15)               0.027[a](#jah33501-note-0005){ref-type="fn"}
  Clopidogrel only                     2 (0.7)                8 (2)              0.083                                          2 (2)                5 (4)                 0.182
  Dual antiplatelet therapy            36 (12)                260 (79)           0.001[a](#jah33501-note-0005){ref-type="fn"}   122 (91)             87 (74)               0.001[a](#jah33501-note-0005){ref-type="fn"}
  Statin                               150 (51)               299 (91)           0.001[a](#jah33501-note-0005){ref-type="fn"}   130 (97)             108 (92)              0.093

ACE indicates angiotensin‐converting enzyme; AMI, acute myocardial infarction; ARB, angiotensin receptor blocker; ASA, acetyl salicylic acid; CABG, coronary artery bypass grafting; CAD, coronary artery disease; CTO, chronic total occlusion; ICD; internal cardioverter defibrillator; LAD, left artery descending; LVEF, left ventricular ejection fraction; LCX, left circumflex; LMT, left main trunk; PCI, percutaneous coronary intervention; RCA, right coronary artery; RIM, ramus intermedius; STEMI/NSTEMI, (non) ST segment myocardial infarction; VF, ventricular fibrillation; VT ventricular tachycardia.

Indicates statistical significance at *P*\<0.05.

Specifically, in non‐AMI patients a slightly higher rate of VT remained after matching, as well as higher rates of prior heart failure, preexisting ICD, dilative cardiomyopathy, CAD, related PCI and pharmacological treatment, which were not included within the matching process (Table [2](#jah33501-tbl-0002){ref-type="table"} left columns). In contrast, comparing STEMI with NSTEMI patients after matching, slightly different rates of coronary chronic total occlusions (CTO), intracoronary thrombus, PCI at the right coronary artery, and LAD and antiplatelet therapy were still seen (Table [2](#jah33501-tbl-0002){ref-type="table"} right columns).

Figure [2](#jah33501-fig-0002){ref-type="fig"}A (left) illustrates the significantly adverse prognosis for the primary end point of long‐term all‐cause mortality in non‐AMI compared with AMI patients when presenting with concomitant ventricular tachyarrhythmias on hospital admission (primary end point, all‐cause mortality at 2.5 years: 55% versus 43%; log rank *P*=0.001; HR=1.349; 95% CI 1.028--1.536; *P*=0.026). Moreover, Figure [2](#jah33501-fig-0002){ref-type="fig"}B (right) illustrates adverse prognosis for the primary end point in NSTEMI compared with STEMI patients (primary end point, all‐cause mortality at 2.5 years: 45% versus 43%; log rank *P*=0.047; HR=1.372; 95% CI 0.991--1.900; *P*=0.057).

![After propensity score matching, Kaplan--Meier survival curves still demonstrated the association of non‐AMI (left) and NSTEMI (right) patients with the primary end point of long‐term all‐cause mortality at 2.5 years (A) and the secondary end point of all‐cause mortality at 30 days (B). C, Distribution of the primary and secondary end points after propensity score matching. NSTEMI indicates non--ST‐segment--elevation myocardial infarction; AMI, acute myocardial infarction; ICU, intensive care unit; IQR, interquartile range; LVEF, left ventricular ejection fraction; PCI, percutaneous coronary intervention; STEMI, ST‐segment--elevation myocardial infarction.](JAH3-7-e010004-g002){#jah33501-fig-0002}

Figure [2](#jah33501-fig-0002){ref-type="fig"}B (left) shows significantly adverse prognosis for the secondary end point of short‐term all‐cause mortality at 30 days, which was already observed in non‐AMI compared with AMI patients (secondary end point, all‐cause mortality at 30 days: 41% versus 34%; log rank *P*=0.018; HR=1.257; 95% CI 1.028--1.536; *P*=0.026). Accordingly, in‐hospital death at index was significantly higher in non‐AMI compared with AMI patients, whereas rates of first re‐PCI were significantly higher in AMI patients (*P*\<0.05). The latter secondary end points were not significantly different between STEMI and NSTEMI patients (Figure [2](#jah33501-fig-0002){ref-type="fig"}C).

Discussion {#jah33501-sec-0017}
==========

The present study evaluates the differences of prognostic outcomes depending on the presence of AMI, NSTEMI and STEMI in consecutive patients presenting with ventricular tachyarrhythmias and SCA on admission.

This real‐world data suggests that high‐risk patients presenting with ventricular tachyarrhythmias and SCA on admission reveal highest long‐term all‐cause mortality in the absence of AMI compared with AMI patients. Furthermore, NSTEMI patients were associated with higher long‐term all‐cause mortality compared with STEMI patients. Prognostic differences were demonstrated even within multivariable Cox regression models and after propensity‐score matching. Differences of mortality were observed at 30‐days and for in‐hospital mortality at index, especially in non‐AMI compared with AMI patients. Patients with AMI‐related VT were associated with higher mortality when occurring ≥48 hours compared with \<48 hours of AMI onset.

The present study demonstrates that the strongest predictors of long‐term mortality across all analyzed subgroups (ie non‐AMI, AMI, NSTEMI, and STEMI patients) consisted in chronic kidney disease, LVEF \<35%, CPR, and cardiogenic shock, whereas the presence of an ICD was consistently protective. Presumably, most patients died from progressive heart failure because of ischemic cardiomyopathy with concomitant chronic kidney disease, representing utmost impaired prognosis for patients after presenting with ventricular tachyarrhythmias in the presence of a cardiorenal syndrome.[15](#jah33501-bib-0015){ref-type="ref"}, [16](#jah33501-bib-0016){ref-type="ref"} Furthermore, patients presenting with cardiogenic shock are known to be at high risk and associated with adverse short‐ and long‐term prognosis.[17](#jah33501-bib-0017){ref-type="ref"}, [18](#jah33501-bib-0018){ref-type="ref"}, [19](#jah33501-bib-0019){ref-type="ref"} In the present study, non‐AMI patients and NSTEMI patients consisted of patients with pre‐existing heart failure with prior CAD, where index ventricular tachyarrhythmias represent disease progression and therefore may indicate the worse future outcome both at short‐ and long‐term follow‐up. In contrast, in STEMI patients the infarct itself may represent the index cause for ventricular tachyarrhythmias and heart failure was not present before. This is supported by the presented data revealing higher rates of preserved LVEF at index in STEMI patients, which may explain the better outcome of STEMI compared with NSTEMI patients. Slight differences of statin and dual antiplatelet therapies may have had further minor impact on mortality differences in STEMI versus NSTEMI patients.

Within the present study, at least 64% of patients in each subgroup underwent CPR related to ventricular tachyarrhythmias reflecting hemodynamic instability and cardiogenic shock. However, PCI rates were higher in AMI compared with non‐AMI patients (un‐matched: 83% \[93% STEMI versus 77% NSTEMI\] versus 19%; matched: 80% \[94% STEMI versus 76% NSTEMI\] versus 22%) alongside with a high rate of coronary multivessel disease in at least 50% and LVEF \<35% in at least 30% of patients in each subgroup. These rates support the need for an invasive strategy by coronary angiography at index hospitalization to treat or exclude relevant CAD. Adequate timing of coronary angiography may not be drawn from the present study. However, it has recently been demonstrated that 30‐day mortality is increased by immediate multivessel PCI in patients presenting with cardiogenic shock and coronary multivessel disease compared with immediate PCI of the culprit lesion only.[29](#jah33501-bib-0029){ref-type="ref"}, [30](#jah33501-bib-0030){ref-type="ref"} The prognostic benefit of an immediate coronary angiography in patients presenting with out‐of‐hospital cardiac arrest and NSTEMI is currently evaluated within the prospective randomized controlled TOMAHAWK study (ClinicalTrials.gov Identifier: NCT02750462), hypothesizing that an immediate coronary angiography may not be associated with a certain prognostic benefit in these high‐risk patients. Accordingly, within the present study index PCI was only of prognostic benefit in AMI, respectively STEMI patients, but not in NSTEMI and non‐AMI patients. Furthermore, AMI patients revealed a significantly higher rate of re‐PCI secondary to ventricular tachyarrhythmias. However, treatment of the most prognosis‐limiting comorbidities of heart failure and chronic kidney disease may take even more notice in non‐AMI and NSTEMI patients.

VF occurs mostly in the presence of acute myocardial ischemia, whereas VT represents a scar‐related substrate in the presence of prior heart failure due to ischemic cardiomyopathy, structural or inflammatory heart disease.[8](#jah33501-bib-0008){ref-type="ref"} Accordingly, international guidelines indicate emergency invasive coronary angiography in patients with acute heart failure or cardiogenic shock complicating AMI (class of recommendation I, level of evidence B).[5](#jah33501-bib-0005){ref-type="ref"}, [19](#jah33501-bib-0019){ref-type="ref"}, [20](#jah33501-bib-0020){ref-type="ref"}, [21](#jah33501-bib-0021){ref-type="ref"}, [22](#jah33501-bib-0022){ref-type="ref"}, [23](#jah33501-bib-0023){ref-type="ref"} In cardiogenic shock and STEMI, international guidelines recommend emergency coronary angiogram to revascularize acutely the potential coronary culprit lesion. However, this is almost based on consensus rather than evidence (class of recommendation I, varying level of evidence B‐C).[5](#jah33501-bib-0005){ref-type="ref"}, [20](#jah33501-bib-0020){ref-type="ref"}, [21](#jah33501-bib-0021){ref-type="ref"}, [24](#jah33501-bib-0024){ref-type="ref"}, [25](#jah33501-bib-0025){ref-type="ref"}, [26](#jah33501-bib-0026){ref-type="ref"} In NSTEMI patients with at least one high risk criterion, immediate invasive coronary angiography is recommended within 2 hours, because a poor short‐ and long‐term prognosis is assumed.[7](#jah33501-bib-0007){ref-type="ref"}, [10](#jah33501-bib-0010){ref-type="ref"}, [27](#jah33501-bib-0027){ref-type="ref"} In contrast, the management of patients with out‐of‐hospital cardiac arrest without ST elevation on the ECG is recommended to be individualized by differentiation of conscious from comatose survivors and a multidisciplinary approach to discriminate coronary from non‐coronary conditions.[10](#jah33501-bib-0010){ref-type="ref"}

Presumably overall 6% of AMI patients develop VT or VF within 48 hours of acute ischemia usually before or during reperfusion therapy.[8](#jah33501-bib-0008){ref-type="ref"}, [28](#jah33501-bib-0028){ref-type="ref"} In acute STEMI non‐sustained VT may occur in 13% and VF in 3%.[12](#jah33501-bib-0012){ref-type="ref"} The present study revealed higher rates of VT \<48 hours compared with VT ≥48 hours (24% versus 7%, excluding early cardiac deaths) in the subgroup of high‐risk AMI patients. The relationship between early VT/VF (\<48 hours) and mortality remains controversial indicating increased 30‐day mortality without protracted risk at long‐term follow‐up especially for early monomorphic VT during AMI.[28](#jah33501-bib-0028){ref-type="ref"}, [29](#jah33501-bib-0029){ref-type="ref"} In contrast, the present study demonstrated significantly higher mortality for patients with AMI‐related VT ≥48 compared with \<48 hours both at short‐ and long‐term follow‐up. Indication for coronary angiography in high‐risk AMI patients is based on expert consensus (class of recommendation I, level of evidence C). The present results, therefore, add knowledge to recent observational studies.[12](#jah33501-bib-0012){ref-type="ref"}

Study Limitations {#jah33501-sec-0018}
-----------------

This observational and retrospective registry‐based analysis reflects a realistic picture of consecutive healthcare supply of high‐risk patients presenting with ventricular tachyarrhythmias and SCA on hospital admission stratified into non‐AMI, AMI, NSTEMI, and STEMI. Lost to follow‐up rate regarding the evaluated end point of all‐cause mortality was minimal. Despite reasonable statistical evaluation implementing to balance this real‐life study population against confounding including multivariable Cox regression and propensity‐score matching results may not be overinterpreted, since propensity matching can only be performed for known patient characteristics. Absence of coronary angiography was mainly attributed to patients with prolonged hemodynamic instability and lethal outcome already at hospital admission (rate of early cardiac death: 30% in this cohort). Patients not surviving out‐of‐hospital CPR without transfer to the heart center were therefore not included in this study. The individual assessment of neurological outcomes and details towards out‐of‐hospital care in case of out‐of‐hospital cardiac arrest was documented incompletely and may have had further prognostic impact.

Conclusions {#jah33501-sec-0019}
===========

Non‐AMI patients were associated with higher all‐cause mortality compared with AMI patients, whereas NSTEMI was associated with higher mortality compared with STEMI in high‐risk patients presenting with ventricular tachyarrhythmias and SCA on admission.
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